Table 3.

Case Series of CAR-T Therapy in Solid Organ Transplant

Baseline Characteristics					Disease Characteristics			Therapies Before CAR-T	Immunosuppression Management	CAR-T Adverse Events and Outcomes
Publication	Case #	Age, Gender	Organ Transplant	Immunosuppression	Time from tx (years)	Timor EBV Static	Pathology			CRS Grade	Outcomes
Krishnamoorthy	1	54M	DDKT/Pancreas	Tac/Aza/Pred	20	Negative	DLBCL-GCB	Rituximab alone, R–CHOP	Low-dose tac, pred	1	Death at day 115 due to refractory PTLD
	2	54F	Heart	Tac/MMF/Pred	26	Negative	DLBCL-non-GCB	R–CHOP, R-ICE, lenalidomide	switched from tac tosirolimus	2	AKI requiring RRT, death at day 44 due to GI bleed from refractory PTLD
	3	71M	DDKT	Tac/Aza/Pred	10	Negative	DLBCL-non-GCB	R–CHOP, R-DHAX, ibrutinib.	Stopped	3	AKI requiring RRT, aspergillus pneumonia, VRE bacteremia, death at day 15 from refractory PTLD
Mamlouk	4	38M	Kidney	Tac/MMF/Pred	10	Negative	DLBCL-GCB	R-EPOCH, R-GEM-Ox	M MF. On low dose pred	1	Rejection at 16 weeks, CR at 1 month, up to 7 mo.
	5	44M	Kidney	Sirolimus/Pred	10	Negative	DLBCL-GCB	R–CHOP	Stopped	1	Pneumonia, AW, CR at 1 mo. Relapse at 34 week
	6	41M	Kidney	Sirolimus/Pred	7	Negative	DLBCL-GCB	R-EPOCH, R-GDP, R- ESHAP, Pola-BR	Stopped sirolimus, on low dose pred	None	PR at 1 mo. PD at 3 mo.
Luttwak	7	69 M	DDKT	Tac	25	Negative	DLBCL-GCB	R-daEPOCH, R-GDP, Pola-BR	Tac (2 ng/mL)	1	CR at 1 mo. Relapse at 3 mo.
	8	50F	DDKT	Tac	5	Negative	DLBCL-GCB	R–CHOP, R-ICE + ASCT, gemcitabine	Tac (2 ng/mL)	2	CR at 1 mo. Sustained at 3 mo.
	9	66M	Liver	Tac	8	Negative	DLBCL-non-GCB	R–CHOP, ICE, radiotherapy	Tac (2 ng/mL)	1	PR at 1 mo. Sustained at 3 mo.
Dang	10	17F	Heart	Tac/Pred	0.3	Positive	DLBCL-non-GCB	CYVE, O-ICE, radiation, EBV-CTL, radiation	Pred, low dose tac (1-2 ng/mL)	1	CR at 1 mo. Sustained at 6 mo.
Wang	11	3M	Liver	Tac/Pred	1.8	Positive	Burkitt lymphoma	R–CP, CP, radiation	Pred	2	CR at 2 mo. Sustained at 16 mo.

Abbreviations: ASCT, autologous stem cell transplantation; Aza, azathioprine; CR, complete response; DDKT, deceased kidney transplant; DLBCL, diffuse large B-cell lymphoma; EBV-CTL, EB virus-specific cytotoxic T cell therapy; GCB, germinal center B cell; GDP, gemcitabine, carboplatin and dexamethasone; MMF, mycophenolate mofetil; PR, partial response; PD, progressive disease; Pola-BR, polatuzumab vedotin, bendamustine, rituximab; R–CHOP: rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone; R-daEPOCH, rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; R-DHAX, Rituximab, dexamethasone, cytarabine, and oxaliplatin; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; R-ESHAP, rituximab, etoposide, methylprednisolone,cytarabine, cisplatin; R-GEM-Ox, rituximab, gemcitabine, oxaliplatin; R-ICE, Rituximab, ifosfamide, carboplatin, and etoposide; RRT, renal replacement therapy; Tac, tacrolimus.

Adapted from Schreiber et al.¹¹⁰